MedTrace Logo

Topical Bromfenac for Intraoperative Miosis and Pain Reduction

NCT03831984 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-02-06

No results posted yet for this study

Summary

To evaluate the effect of bromfenac ophthalmic solution 0.09% for reduction of intraoperative miosis and pain in patient who have undergone femtosecond laser-assisted cataract surgery.

Conditions

  • Cataract

Interventions

DRUG

0,09% Bromfenac

topical 0,09% Bromfenac, one drop twice daily 3 days before surgery

DRUG

0,1% sodium hyaluronate

topical 0,1% sodium hyaluronate, one drop twice daily 3 days before surgery

Sponsors & Collaborators

  • Hospital de La Luz

    lead OTHER

Principal Investigators

  • MARIA AGUILAR SIERRA, MD · FELLOWSHIP

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2018-11-30
Completion
2019-03-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03831984 on ClinicalTrials.gov